Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ACE inhibitor drug reduces heart failure in high-risk patients

25.02.2003


The drug ramipril significantly reduced the onset of debilitating and often-fatal heart failure in a large group of high-risk patients, researchers report in today’s rapid access issue of Circulation: Journal of the American Heart Association.



Ramipril, trade-named Altace, is one of a family of high blood pressure medications known as ACE inhibitors. The drugs reduce the risk of death from heart failure – the inability of a weakened or damaged heart to pump enough blood through the body – in people who suffer heart attacks. The American Heart Association estimates that nearly 5 million people in the United States have congestive heart failure.

"This trial extends the benefits of ACE inhibitors beyond what has been previously proven," says lead author Malcolm Arnold, M.D., "It shows, for the first time, that heart failure can be prevented in a broad range of high risk patients."


Researchers found that ramipril reduced the risk of heart failure by 23 percent in patients with cardiovascular disease who still had normal heart pumping function and no previous heart failure. Patients who received the drug also had a lower rate of hospitalization and death because of heart failure.

"The reduction of heart failure in people treated with ramipril was consistent in all major subgroups," says Arnold, professor of medicine, physiology, and pharmacology at the University of Western Ontario and a cardiologist at the London Health Sciences Center in London, Ontario, Canada. "These included patients over 65 years, females, and patients without known hypertension or diabetes." The trial is from the Heart Outcomes Prevention Evaluation (HOPE) study, a randomized trial that followed 9,541 high-risk cardiovascular patients age 55 and older at 267 centers in 19 countries in the Americas and Europe.

In the new analysis, the researchers used data from 9,297 of the HOPE participants who had randomly received either 10 milligrams of ramipril or a placebo daily and were followed for an average of 4.5 years. Their average age was 66 and 73 percent were males. Fifty-three percent had a previous heart attack, 47 percent had a history of hypertension, and 38 percent had diabetes – all risk factors for heart failure.

Researchers defined heart failure as any of the following: poor heart pumping that caused death, or required hospitalization or treatment with ACE inhibitors as determined by a physician, or the appearance of the disease’s typical signs and symptoms. One or more of these components occurred in 951 (10.2 percent) of the participants during the follow-up period.

Ramipril reduced the rate of heart failure by a significant 22 percent in the 8,315 patients who did not suffer a heart attack. Among the 1,029 people who had a heart attack, those taking ramipril had a 13 percent lower rate of heart failure, although this finding did not reach statistical significance, Arnold says.

In addition, patients treated with ramipril whose systolic blood pressure (the upper number in a blood pressure reading) was above the median had a 33 percent reduction in risk of heart failure compared to a 9 percent reduction for those below the median.

In an accompanying editorial, Jennifer V. Linseman, Ph.D., and Michael R. Bristow, M.D., Ph.D., of the University of Colorado Health Sciences Center in Denver, note that for a majority of the participants in this analysis were classified with heart failure if their symptoms were severe enough that they need to be treated with ACE inhibitors.

This is a "softer endpoint that death or hospitalization . . . ." they write. "Therefore results, while still encouraging, should be viewed with some caution."

Taken with previous results from the HOPE study, they say: "these data support the idea that ACE inhibitors exert a measurable cardiovascular-protective effect in a broad range of patients at high-risk of cardiovascular complications, and these effects are additional to and independent of blood pressure lowering."

Arnold’s co-authors are Salim Yusuf, M.D.; James Young, M.D.; James Mathew, M.D.; David Johnstone, M.D.; Alvaro Avezum, M.D.; Eva Lonn, M.D.; Janice Pogue; and Jackie Bosch on behalf of the HOPE investigators.


CONTACT: For journal copies only, please call: 214-706-1396

For other information, call:
Carole Bullock: 214-706-1279
Bridgette McNeill: 214-706-1135

Carole Bullock | EurekAlert!
Further information:
http://www.americanheart.org/

More articles from Health and Medicine:

nachricht Vanishing capillaries
23.03.2017 | Technische Universität München

nachricht How prenatal maternal infections may affect genetic factors in Autism spectrum disorder
22.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

When Air is in Short Supply - Shedding light on plant stress reactions when oxygen runs short

23.03.2017 | Life Sciences

Researchers use light to remotely control curvature of plastics

23.03.2017 | Power and Electrical Engineering

Sea ice extent sinks to record lows at both poles

23.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>